During Thursday’s Current trade, Shares of Travelers Companies Inc (NYSE:TRV), lost -1.13% to $98.41.
The Travelers Companies, Inc. (TRV) declared that its joint venture with J. Malucelli in Brazil has accomplished the acquisition of a majority interest in Cardinal Compañía de Seguros, a Colombian start-up surety provider. The business, which will continue to be based in Bogotá, will now operate under the co-branded name J. Malucelli Travelers. Terms of the transaction were not revealed.
The Travelers Companies, Inc., through its auxiliaries, provides a range of commercial and personal property, and casualty insurance products and services to businesses, government units, associations, and individuals in the Unites states and internationally. It operates in three segments: Business and International Insurance; Bond & Specialty Insurance; and Personal Insurance.
Shares of Opexa Therapeutics Inc (NASDAQ:OPXA), declined -0.77% to $3.11, during its current trading session.
Opexa Therapeutics, Inc. (OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders counting multiple sclerosis (MS) and neuromyelitis optica (NMO), recently declared that its Board of Directors approved a 1-for-8 reverse stock split of its common stock which will become effective right away following the close of trading September 28, 2015. The merged common shares will start trading on a split-adjusted basis on September 29, 2015 on the NASDAQ Capital Market.
The Company’s shareholders approved the reverse stock split at its annual meeting of shareholders on August 28, 2015, as determined by the Board of Directors in its discretion, at a ratio of not less than 1-for-4 and not more than 1-for-8. The reverse stock split is being implemented by Opexa to maintain the listing of its common stock on the NASDAQ Capital Market. Opexa received a deficiency notice from NASDAQ in December 2014 and, following a 180-day cure period, received an additional 180 days from NASDAQ in June 2015 to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s common stock must be at least $1.00 per share for a minimum of ten successive business days (or such longer period of time as the NASDAQ staff may require) before November 30, 2015. There can be no assurance that the reverse stock split will have the desired effect of raising the closing bid price of Opexa’s common stock proceeding to such date to meet this requirement.
Opexa Therapeutics, Inc., a biopharmaceutical company, develops personalized immunotherapy to treat multiple sclerosis (MS) and other autoimmune diseases, such as neuromyelitis optica (NMO) based on its proprietary T-cell technology.
Cirrus Logic, Inc. (NASDAQ:CRUS), during its Thursday’s current trading session decreased -2.67% to $30.60.
Cirrus Logic, Inc. ( CRUS) declared that the company will post its second quarter fiscal year 2016 financial results and business outlook on the investor relations area of its website on Wednesday, Oct. 28, at about 4 p.m. EDT.
Cirrus Logic will host a live Q&A webcast session at 5 p.m. EDT that same day to answer questions related to its financial results and business outlook. Shareholders who would like to submit a question to be addressed during the call are requested to email [email protected].
Cirrus Logic, Inc., a fabless semiconductor company, develops analog and mixed-signal integrated circuits for a range of consumer and industrial markets. It offers audio products, counting codecs, analog-to-digital converters, digital-to-analog converters, active noise cancelling circuits, amplifiers, and micro-electromechanical system microphones, in addition to standalone digital signal processors.
Finally, Neurocrine Biosciences, Inc. (NASDAQ:NBIX), decreased -1.63%, to $39.12.
Neurocrine Biosciences, Inc. (NBIX) declared that it has designated George J. Morrow to its Board of Directors. Mr. Morrow has over three decades of global pharmaceutical commercial operations leadership experience with Amgen, Glaxo Wellcome, and Merck. He was most recently the Executive Vice President, Global Commercial Operations at Amgen.
Mr. Morrow served as Executive Vice President, Global Commercial Operations at Amgen Inc., a global biotechnology company, from 2003 until his retirement in 2011. He joined Amgen in 2001 as Executive Vice President, Worldwide Sales and Marketing. His responsibilities comprised of oversight of all commercial functions for Amgen’s broad spectrum of products in more than 50 countries worldwide, and the introduction of multiple new products into global markets. From 1992 to 2001, Mr. Morrow held executive administration and commercial positions within several auxiliaries of Glaxo Wellcome, counting Group Vice President for Commercial Operations (U.S.), Managing Director (U.K.), and most recently as President and Chief Executive Officer of Glaxo Wellcome, Inc. (U.S.).
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
